One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Tuesday, as the share price of this fund traded down over 2% in the day’s session. The fund’s share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 228,234 shares of Takeda Pharma. At Tuesday’s closing price, this would have valued this sale at roughly $3.9 million. This is only a small fraction of the total holdings. This fund is up 88% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | TCSLI | TCS GROUP HOLDING PLC | 50,650 |
| ARKG | PSTI | PLURISTEM THERAPEUTICS INC | 1,131 |
| ARKG | NVS | NOVARTIS AG | 139,576 |
| ARKG | SRPT | SAREPTA THERAPEUTICS INC | 48,004 |
| ARKG | TAK | TAKEDA PHARMACEUTICAL CO LTD | 228,234 |
| ARKK | ICE | INTERCONTINENTAL EXCHANGE INC | 196,304 |
| ARKQ | TER | TERADYNE INC | 23,160 |
| ARKQ | RAVN | RAVEN INDUSTRIES INC | 32,733 |
| ARKQ | GLEO | GALILEO ACQUISITION CORP | 5,888 |
| ARKW | NET | CLOUDFLARE INC | 72,257 |
| ARKX | AIRFP | AIRBUS SE | 16,050 |
[nativounit]
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=896738][wallst_email_signup]